Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake.
Animals
Apoptosis
Cell Proliferation
Humans
Liver
/ metabolism
Mice
Mice, Inbred BALB C
Mice, Nude
Molecular Imaging
/ methods
Pancreatic Neoplasms
/ diagnostic imaging
Peptide Fragments
/ immunology
Radiopharmaceuticals
/ metabolism
Receptor, ErbB-3
/ immunology
Recombinant Fusion Proteins
/ immunology
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
01 05 2019
01 05 2019
Historique:
received:
05
12
2018
accepted:
12
04
2019
entrez:
3
5
2019
pubmed:
3
5
2019
medline:
24
10
2020
Statut:
epublish
Résumé
Human epidermal growth factor receptor type 3 (HER3) plays a crucial role in the progression of many cancer types. In vivo radionuclide imaging could be a reliable method for repetitive detection of HER3-expression in tumors. The main challenge of HER3-imaging is the low expression in tumors together with endogenous receptor expression in normal tissues, particularly the liver. A HER3-targeting affibody molecule labeled with radiocobalt via a NOTA chelator [
Identifiants
pubmed: 31043683
doi: 10.1038/s41598-019-43145-2
pii: 10.1038/s41598-019-43145-2
pmc: PMC6494909
doi:
Substances chimiques
Peptide Fragments
0
Radiopharmaceuticals
0
Recombinant Fusion Proteins
0
ERBB3 protein, human
EC 2.7.10.1
Receptor, ErbB-3
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6779Références
An Acad Bras Cienc. 2016;88 Suppl 1:565-77
pubmed: 27275646
Int J Oncol. 2017 Dec;51(6):1765-1774
pubmed: 29039474
J Mammary Gland Biol Neoplasia. 2008 Jun;13(2):225-33
pubmed: 18425425
Cancer. 2015 Oct 15;121(20):3600-11
pubmed: 26195293
Protein Eng Des Sel. 2011 Apr;24(4):385-96
pubmed: 21177282
Clin Pharmacol Ther. 2010 May;87(5):586-92
pubmed: 20357763
Oncol Rep. 2015 Aug;34(2):1042-8
pubmed: 26059265
Recent Pat Anticancer Drug Discov. 2016;11(3):267-74
pubmed: 27086600
Pharmacol Ther. 2014 Jul;143(1):1-11
pubmed: 24513440
PLoS One. 2013 May 10;8(5):e62791
pubmed: 23675426
J Nucl Med. 2009 Feb;50(2):274-83
pubmed: 19164241
Lancet Oncol. 2010 Oct;11(10):992-1000
pubmed: 20667780
Sci Rep. 2017 Feb 23;7:43118
pubmed: 28230065
Trends Biotechnol. 2017 Aug;35(8):691-712
pubmed: 28514998
N Biotechnol. 2018 Oct 25;45:69-79
pubmed: 29574274
Eur J Nucl Med Mol Imaging. 2010 Mar;37(3):613-22
pubmed: 19838701
Cancer Biother Radiopharm. 2005 Jun;20(3):239-48
pubmed: 15989469
Bioconjug Chem. 2016 Aug 17;27(8):1839-49
pubmed: 27357023
Sci Rep. 2015 Oct 19;5:15226
pubmed: 26477646
Mol Pharm. 2018 Aug 6;15(8):3394-3403
pubmed: 29995421
Q J Nucl Med. 1996 Sep;40(3):209-20
pubmed: 8961800
Mol Cancer. 2014 May 08;13:105
pubmed: 24886126
Eur J Nucl Med Mol Imaging. 2006 Jun;33(6):631-8
pubmed: 16538504
Cancer Res. 2012 Aug 15;72(16):4165-77
pubmed: 22719068
Clin Cancer Res. 2018 Apr 15;24(8):1853-1865
pubmed: 29437790
Theranostics. 2016 Jan 01;6(2):262-71
pubmed: 26877784
Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1450-9
pubmed: 24622956
Cancer Res. 2009 Dec 15;69(24):9330-6
pubmed: 19934333
J Nucl Med. 2014 May;55(5):730-5
pubmed: 24665085
Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5021-6
pubmed: 21385943
Eur J Nucl Med Mol Imaging. 2009 Apr;36(4):692-701
pubmed: 19066886
Br J Cancer. 2008 Nov 4;99(9):1415-25
pubmed: 18841159
Nat Rev Clin Oncol. 2010 Mar;7(3):139-47
pubmed: 20125090